PURE Bioscience Schedules Second Quarter 2009 Financial Results Conference Call for March 12, 2009 at 1:30 P.M. PDT
10 Março 2009 - 3:15PM
PR Newswire (US)
SAN DIEGO, March 10 /PRNewswire-FirstCall/ -- PURE Bioscience
(NASDAQ: PURE) today announced that Michael L. Krall, President and
CEO, will host a conference call on Thursday, March 12th at 1:30
P.M. PDT to review and discuss second quarter 2009 financial
results. (Logo:
http://www.newscom.com/cgi-bin/prnh/20060119/LATH060LOGO)
Shareholders and other interested parties may participate in the
conference call by dialing 877-407-8033 or (International)
201-689-8033 a few minutes before 1:30 P.M. PDT on March 12th,
2009. The call is being webcast by Vcall and can be accessed at
http://www.purebio.com/. Investors can also access the webcast at
http://www.investorcalendar.com/. The webcast will be available for
replay through June 13th, 2009. A replay of the conference call
will be accessible until May 13th, 2009 by dialing 877-660-6853 or
(International) 201-612-7415 and entering the Account#: 286 and the
Conference ID#: 316499. About PURE Bioscience PURE Bioscience
develops and markets technology-based bioscience products that
provide solutions to numerous global health challenges, including
Staph (MRSA). PURE's proprietary high efficacy/low toxicity
bioscience technologies, including its silver dihydrogen
citrate-based antimicrobials, represent innovative advances in
diverse markets and lead today's global trend toward industry and
consumer use of "green" products while providing competitive
advantages in efficacy and safety. Patented SDC is an
electrolytically generated source of stabilized ionic silver which
formulates well with other compounds. As a platform technology, SDC
is distinguished from competitors in the marketplace because of its
superior efficacy, reduced toxicity and the inability of bacteria
to form a resistance to it. PURE is headquartered in El Cajon,
California (San Diego metropolitan area). Additional information on
PURE is available at http://www.purebio.com/. PURE Investor
Contact: Paul G. Henning, Vice President Cameron Associates (212)
554-5462 http://www.newscom.com/cgi-bin/prnh/20060119/LATH060LOGO
http://photoarchive.ap.org/ DATASOURCE: PURE Bioscience CONTACT:
Paul G. Henning, Vice President of Cameron Associates,
+1-212-554-5462, , for PURE Bioscience Web Site:
http://www.purebio.com/
Copyright